Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος [ Τύπος(Asc)] Έτος
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
Journal Article
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?. Curr Vasc Pharmacol. 14(3), 271-4.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.. Open Cardiovasc Med J. 5, 85-9.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  Dyslipidemia as a risk factor for ischemic stroke.. Curr Top Med Chem. 9(14), 1291-7.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.. Open Cardiovasc Med J. 5, 24-34.
Mikhailidis, D. P., & Athyros V. G. (2014).  Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics.. Nat Rev Cardiol. 11(2), 72-4.
Kakafika, A. I., Liberopoulos E. N., Karagiannis A., Athyros V. G., & Mikhailidis D. P. (2006).  Dyslipidaemia, hypercoagulability and the metabolic syndrome.. Curr Vasc Pharmacol. 4(3), 175-83.
Karagiannis, A., Mathiopoulou L., Tziomalos K., Kontotasios K., Skaperdas A., Florentin M., et al. (2006).  Dry cough as first manifestation of giant-cell arteritis.. J Am Geriatr Soc. 54(12), 1957-8.
Athyros, V. G., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2008).  Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 200(1), 1-12.
Athyros, V. G., Tziomalos K., Mikhailidis D. P., Pagourelias E. D., Kakafika A. I., Skaperdas A., et al. (2007).  Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opin Pharmacother. 8(14), 2267-77.
Anagnostis, P., Paschou S. A., Goulis D. G., Athyros V. G., & Karagiannis A. (2018).  Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?. Maturitas. 108, 45-52.
Athyros, V. G., Doumas M., Imprialos K. P., Stavropoulos K., Georgianou E., Katsimardou A., et al. (2018).  Diabetes and lipid metabolism.. Hormones (Athens). 17(1), 61-67.
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2011).  The DEFINE study: a bright future for CETP inhibitors?. Expert Opin Investig Drugs. 20(3), 311-4.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Current treatment for nonalcoholic fatty liver disease.. Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., Athyros V. G., & Karagiannis A. I. (2016).  Current challenges in antihypertensive treatment in the elderly.. Pol Arch Med Wewn. 126(7-8), 540-51.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  CORONA, statins, and heart failure: who lost the crown?. Angiology. 59(1), 5-8.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2015).  Contrast-Induced Nephropathy: An "All or None" Phenomenon?. Angiology. 66(6), 508-13.
Athyros, V. G., Mitsiou E. K., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?. Curr Vasc Pharmacol. 8(1), 1-4.
Karagiannis, A., Athyros V. G., & Mikhailidis D. P. (2009).  A comparison of the aldosterone-blocking agents eplerenone and spironolactone.. Clin Cardiol. 32(4), 230.
Athyros, V. G., Ganotakis E. S., Tziomalos K., Papageorgiou A. A., Anagnostis P., Griva T., et al. (2010).  Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population.. Curr Med Res Opin. 26(3), 713-9.
Anagnostis, P., Adamidou F., Slavakis A., Polyzos S. A., Selalmatzidou D., Panagiotou A., et al. (2014).  Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study.. Open Cardiovasc Med J. 8, 55-60.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".. Dig Liver Dis. 45(1), 82-3.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.
Doumas, M., Imprialos Κ., Stavropoulos K., Reklou A., Sachinidis A., & Athyros V. G. (2018).  Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.. Curr Pharm Des.
Tziomalos, K., Athyros V. G., & Mikhailidis D. P. (2009).  Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus.. Nat Clin Pract Endocrinol Metab. 5(1), 16-7.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές